85633-97-2

Basic information

• Product Name: 4-(4-(benzylamino)-3-nitrophenyl)-3-methyl-4-oxobutanoic acid
• Synonyms: 4-(4-(benzylamino)-3-nitrophenyl)-3-methyl-4-oxobutanoic acid;4-(4-benzylamino-3-nitro-phenyl)-3-methyl-4-oxo-butyric acid
• CAS NO: 85633-97-2
• Molecular Formula: C₁₈H₁₈N₂O₅
• Molecular Weight: 342.34592
• Mol File: 85633-97-2.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 4-(4-(benzylamino)-3-nitrophenyl)-3-methyl-4-oxobutanoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(4-(benzylamino)-3-nitrophenyl)-3-methyl-4-oxobutanoic acid(85633-97-2)
• EPA Substance Registry System: 4-(4-(benzylamino)-3-nitrophenyl)-3-methyl-4-oxobutanoic acid(85633-97-2)

Safety Data

• Hazardous Substances Data: 85633-97-2(Hazardous Substances Data)

Upstream product

• 85633-96-1 3-methyl-4-oxo-4-(3'-nitro-4'-chloro-phenyl)-butyric acid 
• 100-46-9 benzylamine 

Downstream Products

• 1338058-47-1 ethyl 4-(4-(benzylamino)-3-nitrophenyl)-3-methyl-4-oxo-butanoate 
• 118428-37-8 pimobendan 
• 136609-85-3 6-(3,4-diaminophenyl)-5-methyl-2,3,4,5-tetrahydropyridazin-3-one 
• 77469-62-6 5-methyl-6-[3'-nitro-4'-benzylamino-phenyl]-4,5-dihydro-3(2H)-pyridazinone 

Relevant articles and documents

PYRIDINONES

The present invention encompasses compounds of general formula (I) wherein the groups R1 to R3 and X1 through X6 have the meanings given in the claims and in the specification. The compounds of the invention are suitable for the treatment of diseases characterized by excessive or abnormal cell proliferation pharmaceutical preparations containing such compounds and their uses as a medicament.

PIMOBENDAN MANUFACTURING PROCESS

The present invention generally relates to an improved process for the manufacture of a non- solvated crystalline compound of formula (I). The invention further relates to a new valuable intermediate compound for the commercial synthesis of pimobendan, which is a compound according to formula (I) n MeOH, wherein n is from 1 to 2 molar equivalents. Still further, the invention relates to the use of said intermediate compound or a compound according to formula (I) obtained by the process of the invention, for the manufacture of a pharmaceutical composition.